Paper: “Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome” By Dr. Orrin Devinsky

Summary:

In this double-blind, placebo-controlled trial, we randomly assigned 120 children and young adults with the Dravet syndrome and drug-resistant seizures to receive either cannabidiol oral solution at a dose of 20 mg or placebo, in addition to standard antiepileptic treatment. 14-week treatment period.

Results: The median frequency of convulsive seizures per month decreased from 12.4 to 5.9 with cannabidiol, as compared with a decrease from 14.9 to 14.1 with placebo. The percentage of patients who had at least a 50% reduction in convulsive-seizure frequency was 43% with cannabidiol and 27% with placebo

Devinsky et al. N Engl J Med 2017;376:2011-20.

https://www.nejm.org/doi/10.1056/NEJMoa1611618

Share:

Back